Singapore, March 24, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 32nd ECCMID event from April 23 - 26, 2022.
ECCMID is recognized as the world’s premier Clinical Microbiology & Infectious Diseases event and brings together experts from many fields to present their latest findings, guidelines, and experiences to an audience of 14,000 visitors. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees, allowing for remote and face-to-face opportunities to take part in the multifaceted program.
Credo Diagnostics will showcase the VitaPCR™ instrument, our true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. At the event, we will be providing live hands-on testing and also demonstrate how VitaDataLink, our connectivity software, solves data management issues.
We invite all visitors
- to come and learn why our COVID-19 solution is now used in many parts of the world – from mobile drive through testing stations, to major airports, cruise ships, laboratories, oil drilling platforms and even onboard the frigates of a major European Navy fleet
- to visit us and find out why our solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests
We look forward to receiving all visitors to our Booth No.2-19.2.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.